JP2015519396A5 - - Google Patents

Download PDF

Info

Publication number
JP2015519396A5
JP2015519396A5 JP2015517311A JP2015517311A JP2015519396A5 JP 2015519396 A5 JP2015519396 A5 JP 2015519396A5 JP 2015517311 A JP2015517311 A JP 2015517311A JP 2015517311 A JP2015517311 A JP 2015517311A JP 2015519396 A5 JP2015519396 A5 JP 2015519396A5
Authority
JP
Japan
Prior art keywords
cancer
compound
salt
inden
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015517311A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015519396A (ja
JP6092376B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/044211 external-priority patent/WO2013188184A1/en
Publication of JP2015519396A publication Critical patent/JP2015519396A/ja
Publication of JP2015519396A5 publication Critical patent/JP2015519396A5/ja
Application granted granted Critical
Publication of JP6092376B2 publication Critical patent/JP6092376B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015517311A 2012-06-14 2013-06-05 Jak1およびjak2の阻害剤 Expired - Fee Related JP6092376B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261659679P 2012-06-14 2012-06-14
US61/659,679 2012-06-14
PCT/US2013/044211 WO2013188184A1 (en) 2012-06-14 2013-06-05 Inhibitor of jak1 and jak2

Publications (3)

Publication Number Publication Date
JP2015519396A JP2015519396A (ja) 2015-07-09
JP2015519396A5 true JP2015519396A5 (enExample) 2016-06-30
JP6092376B2 JP6092376B2 (ja) 2017-03-08

Family

ID=48626679

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015517311A Expired - Fee Related JP6092376B2 (ja) 2012-06-14 2013-06-05 Jak1およびjak2の阻害剤

Country Status (14)

Country Link
US (1) US9062050B2 (enExample)
EP (1) EP2861231B1 (enExample)
JP (1) JP6092376B2 (enExample)
KR (1) KR20150008907A (enExample)
CN (1) CN104349775B (enExample)
AU (1) AU2013274641B2 (enExample)
BR (1) BR112014030651A2 (enExample)
CA (1) CA2871659C (enExample)
EA (1) EA201492104A1 (enExample)
ES (1) ES2605827T3 (enExample)
IN (1) IN2014MN02228A (enExample)
MX (1) MX2014015271A (enExample)
WO (1) WO2013188184A1 (enExample)
ZA (1) ZA201407940B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR105400A1 (es) * 2015-08-04 2017-09-27 Lilly Co Eli Inhibidores de jak1
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN110229067A (zh) * 2019-06-05 2019-09-13 南京焕然生物科技有限公司 一种2-氨基茚制备方法
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN115141195B (zh) * 2021-03-03 2024-02-06 成都先导药物开发股份有限公司 一种nuak抑制剂及其用途
WO2023086320A1 (en) * 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of jak2
CN116585312A (zh) * 2023-04-30 2023-08-15 兰州大学第二医院 含苯氧基丙酸化合物的胰腺癌jak2和stat3双靶向抑制剂及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006087530A1 (en) 2005-02-16 2006-08-24 Astrazeneca Ab Chemical compounds
TWI398252B (zh) * 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
US20100204246A1 (en) * 2007-04-18 2010-08-12 Astrazeneca Ab 5-aminopyrazol-3-yl-3h-imidazo (4,5-b) pyridine derivatives and their use for the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2015519396A5 (enExample)
IL288341B (en) Targeted ligands for medicinal compounds, methods for their preparation and uses thereof
JP2014502638A5 (enExample)
PH12016501972B1 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
JP2017505782A5 (enExample)
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
NZ779654A (en) Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs
MX2015017201A (es) Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga.
JP2016501221A5 (enExample)
GEP20237479B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
NZ706836A (en) Methods of treating cancer
JP2016533366A5 (enExample)
JP2017514855A5 (enExample)
EA032972B1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
JP2017519027A5 (enExample)
RU2016146119A (ru) Новый кристалл тетрациклического соединения
EP3666273A3 (en) Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
EA201391171A1 (ru) Формы рифаксимина и их применение
WO2013040227A3 (en) Therapeutic compounds
JP2013541586A5 (enExample)
JP2014508784A5 (enExample)
JP2015506352A5 (enExample)
IL238722B (en) New annals of indole for the treatment of cancer, viral infections, and lung disease
JP2013540778A5 (enExample)
HK1198690A1 (en) Therapeutic use of imidazopyridine derivatives